Skip to main content
Premium Trial:

Request an Annual Quote

NIDCR to Award $2.5M Through 2009 to Use Gene Silencing for Oral Disease

NEW YORK (GenomeWeb News) - The National Institute of Dental and Craniofacial Research plans to award $2.5 million over two years to support the application of gene silencing to prevent and treat oral and craniofacial disorders and disease.
In a funding announcement released Friday, NIDCR said it is seeking research projects that will use “simple genetic interventions,” including RNA interference, to “modify the expression of genes associated with oral, dental, and craniofacial diseases and disorders.”
Applicants “should demonstrate that the proposed oligonucleotide-based approaches directly influence molecular, biochemical, electrophysiological or other functional changes in a condition that falls within the NIDCR mission area,” the institute said. These areas include tooth and bone disorders, oral cancer, chronic inflammatory conditions, viral infections, autoimmune disorders, craniofacial birth defects, acute and chronic pain conditions, salivary gland dysfunction, and other oral, dental, and craniofacial disorders.
NIDCR said it plans to award around $2.5 million in fiscal years 2008 and 2009 to between five and 10 grants, pending availability of funds.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.